Filing Flows

Filing Flows › Companies › Allarity Therapeutics › Cash flow

Allarity Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.6M in Q2 2026 · −$13.8M over twelve months

Operating cash flow−$2.6M
Free cash flow−$2.6M

Analysis

In Q2 2026, Allarity Therapeutics generated −$2.6M of operating cash flow. That is $2.9M more than in Q2 2025 (−$5.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$13.7M; the largest uses were operating cash flow ($13.7M), buybacks ($887K), capital spending ($72K); besides operations, cash came from other financing ($22.7M); the cash balance rose by $9.2M.

Operating cash flow was −$2.6M against net income of −$3.4M. The largest differences: accrued liabilities −$220K, stock-based pay +$188K, payables −$122K.

Free cash flow

Allarity Therapeutics: free cash flow by quarterAllarity Therapeutics: free cash flow by quarter−$5.4MQ3 2024−$3.2MQ4 2024−$2.7MQ1 2025−$5.5MQ2 2025−$3.4MQ3 2025−$3.2MQ4 2025−$4.6MQ1 2026−$2.6MQ2 2026
Operating cash flow less capital spending.
Allarity Therapeutics: operating cash flow against capital spendingAllarity Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$5.4M$0Q3 2024−$3.2M$0Q4 2024−$2.7M$0Q1 2025−$5.5M$0Q2 2025−$3.4M$0Q3 2025−$3.2M$0Q4 2025−$4.5M$64KQ1 2026−$2.6M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.6M, Capital spending $0.

Capital allocation, year by year

Allarity Therapeutics: where the cash came from (up) and went (down), by fiscal yearAllarity Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$14.9MFY2021: Net borrowing −$84KFY2021: Shares issued $30.6MFY2021: Asset sales $1.0M$31.6MFY2021FY2022: Operating cash flow −$16.8MFY2022: Net borrowing −$1.7MFY2022: Asset sales $809KFY2022: Capital spending −$18K$809KFY2022FY2023: Operating cash flow −$12.7MFY2023: Net borrowing $3.1MFY2023: Shares issued $1.2M$4.3MFY2023FY2024: Operating cash flow −$17.4MFY2024: Shares issued $40.3MFY2024: Capital spending −$298K$40.3MFY2024FY2025: Operating cash flow −$14.8MFY2025: Shares issued $11.1MFY2025: Capital spending −$8KFY2025: Buybacks −$3.2M$11.1MFY2025
Over these 5 years operating cash flow totalled −$76.6M; the largest uses were operating cash flow ($76.6M) and buybacks ($3.2M). Cash-flow statements as filed.

Where the cash came from and went

Allarity Therapeutics: sources (+) and uses (−) of cash, Q2 2026Allarity Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$2.8MOperating cash flow−$2.6MExchange rates−$267K
Allarity Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Allarity Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$22.7MOperating cash flow−$13.7MCash drawn (+) / kept (−)−$9.2MExchange rates$1.2MBuybacks−$887KCapital spending−$72K

From profit to cash

Allarity Therapeutics: net income to operating cash flow, Q2 2026Allarity Therapeutics: net income to operating cash flow, Q2 2026Net income−$3.4MStock-based pay$188KPayables−$122KAccrued liabilities−$220KPrepaid and other assets$47KOperating cash flow−$2.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingBuybacksShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.6M———$2.8M−$2.6M
Q1 2026−$4.5M−$64K−$262K—−$15.1M−$4.6M
Q4 2025−$3.2M—−$484K—$2.2M−$3.2M
Q3 2025−$3.4M—−$141K—$906K−$3.4M
Q2 2025−$5.5M—−$2.6M—$9.9M−$5.5M
Q1 2025−$2.7M——$11.1M−$8.2M−$2.7M
Q4 2024−$3.2M——$4.2M−$1.1M−$3.2M
Q3 2024−$5.4M——$5.4M$770K−$5.4M

Allarity Therapeutics: income statement and cash flow

Allarity Therapeutics, Q1 2026: revenue $25K. The chart follows the revenue to costs, profit and cash.

Allarity Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.